# 1. Financial Performance ## A. Key Figures * Revenue from Operations: ₹598.25 Cr Q2 FY26 (-9% YoY) · ₹654.28 Cr Q2 FY25 * EBITDA: **₹136.73 Cr** Q2 FY26 (+16% YoY) · **₹159.58 Cr** Q2 FY25 * Profit after Tax: **₹93.97 Cr** Q2 FY26 (+87% YoY) · **₹117.52 Cr** Q2 FY25 ## B. Revenue & Profit * **Profitability Surge Despite Sales Dip:** Strong bottom-line growth driven by **favorable cost dynamics** and lower tax incidence, even as top-line declined. * **H2 Recovery Expected:** Management anticipates **2% to 3% growth in H2** to partially offset H1’s **₹21 Cr negative variance**, though full-year outlook remains flat. * **Opex Resilience:** Operating expenses held flat YoY despite lower sales, with **increased marketing spend** offsetting logistics savings, particularly in B2C. ## C. Margins Trend * **Margins Defied Headwinds:** Gross and EBITDA margins remained stable QoQ and YoY despite **loss of high-margin bio products**, supported by operational discipline. * **Revised EBITDA Outlook:** While gross margin is now expected to hold flat vs. prior year, **EBITDA margin to decline ~100 bps** due to structural cost pressures. ## D. Balance Sheet * **Strong Financial Flexibility:** Company remains **debt-free** with a robust balance sheet, positioning it for strategic investments in backward integration and M&A. ## E. Cash Flow * **Working Capital Discipline:** Despite extended receivables, **no significant increase in working capital needs** expected for the year due to tight management controls. --- # 2. Product & Segment Performance ## A. Key Figures * **Revenue Mix (Q2 FY25-26):** **Insecticides (46%)** · **Fungicides (29%)** · **Herbicides (9%)** · **Others (16%)** * **Biostimulants Revenue (Q2):** **₹20+ Cr** (slightly over) * Bayer Royalty Income (Q2): **~₹4.5 Cr** * **Bayer Molecules Revenue (H1):** **₹25 Cr** * **Bio & PTR Products Contribution:** **8–10%** of annual top line ## B. Insecticides & Fungicides * **Core Growth Drivers:** Insecticides and fungicides remain dominant revenue contributors, together accounting for **75% of total sales**, underscoring their strategic importance to the business. ## C. Herbicides Decline * **Portfolio Under Pressure:** Herbicides segment weighed on performance due to **lower margins on key molecules** and **higher returns**, despite resilience in paddy and total weed control categories. * **Demand Recovery Signal:** Positive rabi season outlook supported by **healthy soil moisture and seed demand**, indicating potential near-term stabilization. * **B2C Contraction:** Domestic B2C business declined after adjustments, primarily driven by herbicides and the **biostimulants regulatory ban**, with no evidence of customer shift to generics. ## D. Biostimulants Impact * **Regulatory Transition:** Biostimulants remain a growth avenue despite short-term headwinds from new regulations; the category contributes meaningfully to innovation and portfolio diversification. * **Strategic Expansion:** Successful integration of new agricultural inputs like **MYCORe Super** highlights R&D and commercial capability in emerging input segments. ## E. Bayer Portfolio * **Global Technology Access:** Partnerships with 10 leading agrochemical firms, including Bayer, enable localized delivery of advanced crop protection solutions. * **Revenue Recognition Shift:** Bayer-related revenue from transferred markets will begin reflecting in Dhanuka’s books **from next fiscal year**, with **India business contribution estimated at ~₹30 Cr**. * **Future Margin Upside:** Operating leverage expected to improve once production of Bayer molecules shifts to India, though magnitude remains uncertain. * **Portfolio Enrichment:** Acquisition of **Melody Duo and Triadimenol** global rights strengthens proprietary product pipeline and export potential. --- # 3. Geography & Channel Mix ## A. Key Figures * **Zone-wise Revenue Share:** **33%** South Zone · **30%** North India · **24%** West India · **13%** East India * **Distribution Network:** **4** manufacturing units · **41** warehouses · **6,500** distributors · **80,000** retailers ## B. Zone-wise Sales * **Regional Concentration:** South Zone remains the largest contributor, followed closely by North and West India, indicating strong pan-India penetration with regional leadership. ## C. Distribution Network * **Channel Resilience:** Proactive sales returns management through tight distributor collaboration ensures rapid inventory rotation and product freshness. * **Scalable Infrastructure:** Extensive physical footprint supports wide market coverage and underpins efficient demand fulfillment across geographies. ## D. Farmer Engagement * **Digital-First Outreach:** Strategic shift toward digital platforms (Instagram, Facebook, WhatsApp, YouTube) enhances farmer engagement via live launches and targeted campaigns. * **Technology-Driven Enablement:** Partnerships with agritech start-ups enable precision agriculture solutions, including drone-based spray services in key states and IoT integration for horticulture. * **Institutional Knowledge Transfer:** Dedicated digital training platform with KVKs and agricultural universities strengthens farmer education and adoption of advanced farming practices. * **Monetizable Farmer Connect:** Strong existing relationships and distribution reach provide a scalable platform for future agri-input product expansion. --- # 4. Manufacturing & Capacity ## A. Key Figures * **Dahej Sales:** **₹22 Cr** (quarterly) · **EBITDA Loss:** **₹46 Lakh** (nominal) * **Dahej EBITDA Breakeven:** Now targeted for **FY '27** (revised from FY '26) ## B. Dahej Plant Progress * **New Product Ramp-Up:** Trial production of **Difenoconazole** underway at Dahej, with scale-up pending stabilization; initially focused on Indian market due to cost disadvantages vs. China. * **Progress on Key Products:** **Bifenthrin Technical sales** tracking in line with annual targets; **Iprovalicarb** set for domestic manufacturing launch in **FY '27**. * **Strategic Asset Utilization:** Dahej facility on track for FY '26 revenue goals; company actively exploring **contract manufacturing partnerships** to monetize excess capacity. * **Backward Integration Milestone:** Successful in-house production of a **second active ingredient** strengthens B2B and export platform. ## C. Backward Integration * **Domestic Manufacturing Tailwinds:** India emerging as key agrochemical manufacturing hub amid global supply chain shifts and reduced investment in **Europe, US, and Japan**. * **Supply Chain Development:** Difenoconazole production currently reliant on **Chinese-sourced raw materials**; efforts underway to identify and develop domestic Indian suppliers. --- # 5. Regulatory & Product Updates ## A. Key Figures * Biostimulant Sales Impact: More than INR20 Cr sales impact (pre-halt) · 2.5% to 3% of Q2 sales * **Top-Line Impact:** **~2.5% annual headwind** due to biostimulant ban ## B. Biostimulant Regulations * **Regulatory Resolution in Sight:** Anticipated clearance for proprietary biostimulants under new guidelines, enabling resumption of halted sales and normalization of **~5% annual top-line drag**. * **Market Formalization Accelerating:** Over **146 biostimulants approved** by GoI, with standardized testing protocols and authorized labs, driving sector consolidation. * **Organized Players Gain Advantage:** Increased regulation favors compliant companies like Dhanuka, creating **immediate-term market share opportunities** amid industry disruption. * **Industry Concerns Persist:** New regulations criticized for abrupt rollout and **lack of stakeholder consultation**, though aimed at ensuring quality and curbing malpractice. ## C. New Product Launches * **Ipflufenoquin Launched for Paddy:** First indigenous registration under Section 9(3) for transplanted paddy, targeting **leaf and neck blast**, co-developed with **Nippon Soda, Japan**. ## D. Registration Pipeline * **Robust R&D Backing Registrations:** Proprietary pipeline supported by **two dedicated labs**, including **NABL-accredited facility**, and specialized team managing approvals amid regulatory backlog. --- # 6. Demand & Seasonal Risks ## A. Crop Cycle Delays * **Kharif-Rabi Overlap:** Delayed kharif harvesting has pushed into November–December, postponing rabi sowing and creating a compressed, overlapping crop cycle in major agricultural regions. * **H2 Revenue Headwinds:** Weak October performance and biostimulant segment challenges dampened rabi season momentum, contributing to cautious near-term outlook. ## B. Input Demand Trends * **Farmer Economics Under Pressure:** Revenue outlook tempered by micro-level stressors, including **soybean prices in Maharashtra below MSP**, affecting input investment capacity. * **Post-Sowing Rainfall Critical:** Favorable outlook for wheat, mustard, and Bengal gram if northern India receives sustained rainfall over 30–40 days post-sowing, supporting crop quality and farmer sentiment. --- # 7. Guidance & Outlook ## A. Key Figures * **FY26 Revenue:** **Flat** YoY, with H2 expected stronger than H1 * **Bayer Product Revenue (FY26):** **₹100 Cr** total expected, ₹40 Cr cumulative to date (₹25 Cr from India) * H2 Domestic Revenue Run Rate: ~₹890–900 Cr (guidance), including Dahej; H2 Bayer revenue: ₹15 Cr ## B. H2 Recovery Expectation * **Seasonal Rebound Underway:** H2 revenue momentum expected to improve on favorable soil moisture and water availability, with kharif headwinds fading within a month. * **Near-Term Growth Catalysts:** Biostimulant sales poised to resume by Q1 next fiscal, while Q3 FY26 expected to show **significant sequential improvement** over Q2. * **Strategic Patience Required:** Growth initiatives in a high-potential but long-gestation market, requiring sustained investment and tolerance for near-term volatility. ## C. Long-term Growth Path * **Bayer Rollout to Drive Future Upside:** Full Bayer-related revenue and international royalties delayed to next fiscal due to distributor onboarding and registration lags, implying a step-up in FY27. * **Confidence in Rabi & Rural Macro:** Strong rabi season anticipated on the back of healthy rural economic conditions, supporting optimism for **FY26 and beyond**. * **Growth Commitment Intact:** Despite near-term headwinds, company remains focused on investment, new product launches, and long-term transformation of Indian agriculture.